 |
Companies | Products |
|
|
Products | |
Diseases | |
Trials |  |
News |  |
| «12...123124125126127128129130131132133134135» |
- sirolimus / Generic mfg.
[VIRTUAL] AUTOPHAGY IN ENDOTHELIAL CELLS REGULATES THEIR HAEMATOPOIESIS-SUPPORTING ABILITY (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3131;
Defective autophagy in BM ECs may be involved in the pathogenesis of PGF post-allotransplant. Although further validation is required, our data suggest that improving autophagy in BM ECs may be a potential therapeutic approach in PGF patients after allo-HSCT.
- [VIRTUAL] The bidirectional regulation of the Hippo pathway and autophagy in pancreatic beta cells (Salzburg Hall) - Jul 2, 2020 - Abstract #EASD2020EASD_513;
Although further validation is required, our data suggest that improving autophagy in BM ECs may be a potential therapeutic approach in PGF patients after allo-HSCT. This unravels the novel bidirectional role of the Hippo kinase LATS2 and autophagy in the regulation of beta-cell survival.
- [VIRTUAL] The circadian clock nuclear receptor Rev-erbα is implicated in autophagy alteration and beta cell deficit under diabetogenic conditions (Salzburg Hall) - Jul 2, 2020 - Abstract #EASD2020EASD_512;
Taken together, these data reveal for the first time an underexplored link between the core circadian clock nuclear receptor Rev-erbα, autophagy and beta-cell failure under diabetogenic conditions. These data also suggest a therapeutic potential of elaborating new Rev-erbα-based strategies to preserve a functional beta-cell mass in T2D.
- ||| temuterkib (LY3214996) / Eli Lilly
Enrollment open, Combination therapy, Metastases: LY3214996 +/- HCQ in Pancreatic Cancer (clinicaltrials.gov) - Jun 28, 2020
P2, N=52, Recruiting, Sponsor: Brian Wolpin, MD, MPH
These data also suggest a therapeutic potential of elaborating new Rev-erbα-based strategies to preserve a functional beta-cell mass in T2D. Not yet recruiting --> Recruiting
- | chloroquine phosphate / Generic mfg.
Journal: Autophagy Inhibition Sensitizes Renal Tubular Epithelial Cell to G1 Arrest Induced by Transforming Growth Factor beta (TGF-β). (Pubmed Central) - Jun 23, 2020
Human kidney-2 (HK-2) cells were stimulated by TGF-ß with or without a combined treatment of autophagy inhibitor chloroquine (CQ) or bafilomycin A1 (Baf)...Western blot analysis showed that TGF-ß-induced expression of extracellular matrix fibronectin was notably upregulated in the presence of autophagy inhibitors. CONCLUSIONS Inhibition of autophagy sensitizes the TECs to G1 arrest and proliferation suppression induced by TGF-ß that contributes to the induction of tubulointerstitial fibrosis.
- | New trial: GROSSAUTOP: Autophagy/Apoptosis Balance During Pregnancy (clinicaltrials.gov) - Jun 22, 2020
P, N=120, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de N?mes
- | Sutent (sunitinib) / Pfizer
Trial primary completion date, Metastases: Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy (clinicaltrials.gov) - Jun 18, 2020
P1, N=40, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
CONCLUSIONS Inhibition of autophagy sensitizes the TECs to G1 arrest and proliferation suppression induced by TGF-ß that contributes to the induction of tubulointerstitial fibrosis. Trial primary completion date: Jun 2020 --> Sep 2020
- | monalizumab (IPH2201) / AstraZeneca, Innate, ezurpimtrostat (GNS561) / Genoscience Pharma, Genfit, avdoralimab (IPH5401) / Innate
Trial suspension, Metastases: IMMUNONCOVID: Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection (clinicaltrials.gov) - Jun 15, 2020
P2, N=384, Suspended, Sponsor: Centre Leon Berard
Trial primary completion date: Jun 2020 --> Sep 2020 Recruiting --> Suspended
- | chloroquine phosphate / Generic mfg.
Journal: Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine. (Pubmed Central) - Jun 13, 2020
By elevating the pH of acidic endosomes/lysosomes, CQ/HCQ inhibit the autophagic process. In this short perspective, we discuss the roles of CQ/HCQ in the treatment of COVID-19 patients and propose new ways of possible treatment for SARS-CoV-2 infection based on the molecules that selectivity target autophagy.
- | monalizumab (IPH2201) / AstraZeneca, Innate, ezurpimtrostat (GNS561) / Genoscience Pharma, Genfit, avdoralimab (IPH5401) / Innate
Enrollment change, Metastases: IMMUNONCOVID: Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection (clinicaltrials.gov) - Jun 8, 2020
P2, N=384, Recruiting, Sponsor: Centre Leon Berard
In this short perspective, we discuss the roles of CQ/HCQ in the treatment of COVID-19 patients and propose new ways of possible treatment for SARS-CoV-2 infection based on the molecules that selectivity target autophagy. N=273 --> 384
- [VIRTUAL] Glycogen synthase 2 (gys2) restricts tumor metastatic ability via attenuating autophagy and breaking glycogenic homeostasis in hepatocelluar carcinoma (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1355;
In summary, our findings suggested that GYS2 serves as a prognostic factor and functions as a tumor suppressor by inhibiting autophagy and interpreting glycogenic homeostasis in HCC. GYS2 might be a promising target for prevention, treatment and prognostic prediction of HCC.
- | Journal: Epithelial-mesenchymal transition suppresses ERas to activate autophagy in retinal pigment epithelial cells in proliferative vitreoretinopathy. (Pubmed Central) - May 22, 2020
GYS2 might be a promising target for prevention, treatment and prognostic prediction of HCC. Our study revealed the role of ERas in the pathogenesis of PVR through EMT and provided a novel therapeutic target for PVR prevention and treatment.
- |||| temuterkib (LY3214996) / Eli Lilly
New P2 trial, Combination therapy, Metastases: LY3214996 +/- HCQ in Pancreatic Cancer (clinicaltrials.gov) - May 12, 2020
P2, N=52, Not yet recruiting, Sponsor: Brian Wolpin, MD, MPH
- | Mekinist (trametinib) / Novartis, BeiGene
Enrollment open, Metastases: CHLOROTRAMMEL: MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma (clinicaltrials.gov) - May 7, 2020
P=N/A, N=29, Recruiting, Sponsor: Hospices Civils de Lyon
Our study revealed the role of ERas in the pathogenesis of PVR through EMT and provided a novel therapeutic target for PVR prevention and treatment. Not yet recruiting --> Recruiting
- | xevinapant (AT-406) / Debiopharm, Ascenta
Journal: The Strong Inhibitory Effect of Combining Anti-Cancer Drugs AT406 and Rocaglamide with Blue LED Irradiation on Colorectal Cancer Cells. (Pubmed Central) - May 4, 2020
Furthermore, little to no cell inhibition or damage of normal MRC-5 cells were seen after treatment. The combination of blue LED irradiation and two anti-cancer drugs causes apoptosis of colorectal cancer cells by activating the apoptotic pathway, inhibiting autophagy and proliferation pathways as well as the production of reactive oxygen species (ROS).
- | sirolimus / Generic mfg.
Journal: Autophagy regulates lipid production and contributes to the sebosuppressive effect of retinoic acid in human SZ95 sebocytes. (Pubmed Central) - May 2, 2020
The combination of blue LED irradiation and two anti-cancer drugs causes apoptosis of colorectal cancer cells by activating the apoptotic pathway, inhibiting autophagy and proliferation pathways as well as the production of reactive oxygen species (ROS). Autophagy plays an important role in the modulation of lipogenesis in human sebocytes and is involved in the sebostatic effect of 13-cis-RA.
- | temozolomide / Generic mfg.
Journal: Micro-RNA29b Enhances the Sensitivity of GlioblastomaMultiforme Cells to Temozolomide by Promoting Autophagy. (Pubmed Central) - Apr 11, 2020
Autophagy plays an important role in the modulation of lipogenesis in human sebocytes and is involved in the sebostatic effect of 13-cis-RA. miR-29b potentiates TMZ sensitivity against GBM cells by inducing autophagy and the combined use of miR-29 mimic and TMZ might represent a potential therapeutic strategy for GBM patients.
- | monalizumab (IPH2201) / AstraZeneca, Innate, ezurpimtrostat (GNS561) / Genoscience Pharma, Genfit, avdoralimab (IPH5401) / Innate
Enrollment open, Metastases: IMMUNONCOVID: Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection (clinicaltrials.gov) - Apr 6, 2020
P2, N=273, Recruiting, Sponsor: Centre Leon Berard
miR-29b potentiates TMZ sensitivity against GBM cells by inducing autophagy and the combined use of miR-29 mimic and TMZ might represent a potential therapeutic strategy for GBM patients. Not yet recruiting --> Recruiting
- | monalizumab (IPH2201) / AstraZeneca, Innate, ezurpimtrostat (GNS561) / Genoscience Pharma, Genfit, avdoralimab (IPH5401) / Innate
New P2 trial, Metastases: IMMUNONCOVID: Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection (clinicaltrials.gov) - Apr 2, 2020
P2, N=273, Not yet recruiting, Sponsor: Centre Leon Berard
- | Sutent (sunitinib) / Pfizer
Trial primary completion date, Metastases: Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy (clinicaltrials.gov) - Apr 2, 2020
P1, N=40, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2013 --> Jun 2020
- | Journal: Inhibition of autophagy sensitizes lignan-induced endoplasmic reticulum stress-mediated cell death. (Pubmed Central) - Mar 28, 2020
Furthermore, the cytotoxicity of DFS was potentiated by the co-treatment of autophagy inhibitor in these cancer cells. This study has provided a noble implication that the combination of DFS and autophagy inhibition exerts a synergistic effect in cancer treatment.
- || Review, Journal: Crosstalk between the mTOR and Nrf2/ARE signaling pathways as a target in the improvement of long-term potentiation. (Pubmed Central) - Mar 14, 2020
In this review, we discuss the crosstalk between the Nrf2/ARE signaling and mTOR in the maintenance of synaptic plasticity. Nrf2 pathway can be activated by pharmacological agents and by changes in mitochondria functioning accompanying various neuronal dysfunctions.
- | Journal: Harnessing autophagic network is essential for trophoblast stem cell differentiation. (Pubmed Central) - Mar 10, 2020
In addition, inhibition of autophagy was associated with a decrease in nuclear size of trophoblast giant cells. Taken together, these data highlight that autophagy is a necessary prelude in commitment of trophoblast differentiation from the multipotent trophoblast stem cells probably by regulating protein turnover at the onset of differentiation.
- | Journal: Autophagy inhibition changes the disposition of non-viral gene carriers during blood-brain barrier penetration and enhances TRAIL-induced apoptosis in brain metastatic tumor. (Pubmed Central) - Mar 1, 2020
Besides, Wtmn-Lip synergistically induces apoptosis with TRAIL via different signaling pathways. Herein, pre-treatment of Wtmn-Lip might solve delivery difficulties of non-viral gene carriers in the treatment of brain metastatic cancers.
- bortezomib / Generic mfg.
[VIRTUAL] DOWN REGULATION OF AUTOPHAGY ENHANCES BORTEZOMIB-INDUCED APOPTOSIS OF MYELOMA CELL BY UP REGULATION OF MITOCHONDRIAL REACTIVE OXYGEN SPECIES (ePoster Area) - Feb 8, 2020 - Abstract #EBMT2020EBMT_1647;
Our experiment showed crosstalk between autophagy and mitochondrial ROS and its redox enzymes during BTZ-induced MM cell apoptosis. Inhibition of autophagy with 3-MA potentiates BTZ-induced apoptosis of MM cells via up regulation of mitochondrial ROS.
- sirolimus / Generic mfg.
[VIRTUAL] AUTOPHAGY IN ENDOTHELIAL CELLS REGULATES THEIR HAEMATOPOIESIS-SUPPORTING ABILITY (ePoster Area) - Feb 8, 2020 - Abstract #EBMT2020EBMT_1127;
Defective autophagy in BM ECs may be involved in the pathogenesis of PGF post-allotransplant. Although further validation is required, our data suggest that improving autophagy in BM ECs may be a potential therapeutic approach in PGF patients after allo-HSCT.
- | Journal: MiR-450a-5p inhibits autophagy and enhances radiosensitivity by targeting dual-specificity phosphatase 10 in esophageal squamous cell carcinoma. (Pubmed Central) - Feb 6, 2020
Tumor xenograft experiments verified that miR-450a-5p overexpression could increase sensitivity to radiation therapy in vivo. In general, our findings indicate that miR-450a-5p is a latent radiosensitizer and may represent a potential novel therapeutic target for radioresistance in ESCC.
- | hydroxychloroquine / Generic mfg., docetaxel / Generic mfg., gemcitabine / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy: Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov) - Feb 5, 2020
P1/2, N=31, Recruiting, Sponsor: M.D. Anderson Cancer Center
In general, our findings indicate that miR-450a-5p is a latent radiosensitizer and may represent a potential novel therapeutic target for radioresistance in ESCC. Trial completion date: Mar 2020 --> Mar 2022 | Trial primary completion date: Mar 2020 --> Mar 2022
- | chloroquine phosphate / Generic mfg.
Trial completion: CHLOROBRAIN: The Addition of Chloroquine to Chemoradiation for Glioblastoma (clinicaltrials.gov) - Jan 23, 2020
P1, N=13, Completed, Sponsor: Maastricht Radiation Oncology
Trial completion date: Mar 2020 --> Mar 2022 | Trial primary completion date: Mar 2020 --> Mar 2022 Recruiting --> Completed
- | Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Enrollment open: A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration (clinicaltrials.gov) - Jan 5, 2020
P1/2, N=75, Recruiting, Sponsor: Pediatric Brain Tumor Consortium
Recruiting --> Completed Active, not recruiting --> Recruiting
- | Zolinza (vorinostat) / Merck (MSD)
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer (clinicaltrials.gov) - Jan 3, 2020
P1, N=143, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting Trial completion date: Feb 2021 --> Dec 2021 | Trial primary completion date: Feb 2020 --> Dec 2021
- |||| Cotellic (cobimetinib) / Exelixis, Roche, Tecentriq (atezolizumab) / Roche
New P1/2 trial, Combination therapy, Checkpoint inhibition, PD(L)-1 Biomarker, Checkpoint block, Metastases: MEKiAUTO: Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies (clinicaltrials.gov) - Jan 2, 2020
P1/2, N=175, Not yet recruiting, Sponsor: Columbia University
- | Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
New P1/2 trial: A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration (clinicaltrials.gov) - Dec 17, 2019
P1/2, N=75, Active, not recruiting, Sponsor: Pediatric Brain Tumor Consortium
- | sirolimus / Generic mfg.
Journal: Inducing and Inhibiting Autophagy to Investigate Its Interactions with MIF. (Pubmed Central) - Nov 21, 2019
However, the unprecedented interest in autophagy in recent times has generated a number of tools and techniques for its study. Here, we present protocols for studying the interactions between MIF and autophagy, including for the induction and inhibition of autophagy and measuring autophagosome biogenesis and maturation.
- | Journal: Circ_016719 plays a critical role in neuron cell apoptosis induced by I/R via targeting miR-29c/Map2k6. (Pubmed Central) - Nov 10, 2019
Here, we present protocols for studying the interactions between MIF and autophagy, including for the induction and inhibition of autophagy and measuring autophagosome biogenesis and maturation. Our results suggest that circ_016719 directly targets miR-29c, and thereby regulates the expression and functions of Map2k6, which significantly contributes to the pro-apoptotic role of circ_016719.
- | sirolimus / Generic mfg.
Journal: Dihydromyricetin promotes autophagy and attenuates renal interstitial fibrosis by regulating miR-155-5p/PTEN signaling in diabetic nephropathy. (Pubmed Central) - Nov 1, 2019
In vitro, NRK-52E cells were divided into four groups: normal glucose (NG), high glucose (HG), HG+DHM, and HG+rapamycin (autophagy inhibitor)...In addition, DHM promoted autophagy by inhibiting the PI3K/AKT/mTOR signaling pathway. In conclusion, DHM promotes autophagy and attenuates RIF by regulating the miR-155-5p/PTEN signaling and PI3K/AKT/mTOR signaling pathway in DN.
- | Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date, Surgery: NCI-2018-01050: Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer (clinicaltrials.gov) - Sep 26, 2019
P1/2, N=54, Recruiting, Sponsor: M.D. Anderson Cancer Center
In conclusion, DHM promotes autophagy and attenuates RIF by regulating the miR-155-5p/PTEN signaling and PI3K/AKT/mTOR signaling pathway in DN. Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
- | hydroxychloroquine / Generic mfg., temozolomide / Generic mfg.
Trial completion: Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Jul 10, 2019
P1/2, N=92, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020 Active, not recruiting --> Completed
- | Mekinist (trametinib) / Novartis, BeiGene
New trial, Metastases: CHLOROTRAMMEL: MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma (clinicaltrials.gov) - Jun 6, 2019
P=N/A, N=29, Not yet recruiting, Sponsor: Hospices Civils de Lyon
- | Zolinza (vorinostat) / Merck (MSD)
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer (clinicaltrials.gov) - May 15, 2019
P1, N=143, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial completion date: Apr 2019 --> Feb 2021 | Trial primary completion date: Apr 2019 --> Feb 2020
- | hydroxychloroquine / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date, Combination therapy: A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer (clinicaltrials.gov) - Apr 20, 2019
P1/2, N=119, Active, not recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Trial completion date: Apr 2019 --> Feb 2021 | Trial primary completion date: Apr 2019 --> Feb 2020 Trial primary completion date: Dec 2018 --> Dec 2020
- | hydroxychloroquine / Generic mfg., everolimus / Generic mfg., sirolimus / Generic mfg.
Trial completion: Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma (clinicaltrials.gov) - Apr 20, 2019
P1/2, N=40, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Trial primary completion date: Dec 2018 --> Dec 2020 Active, not recruiting --> Completed
- | hydroxychloroquine / Generic mfg., docetaxel / Generic mfg., gemcitabine / Generic mfg.
Enrollment open, Combination therapy: Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov) - Jan 30, 2019
P1/2, N=31, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Ibrance (palbociclib) / Pfizer
New P1/2 trial, Surgery: NCI-2018-01050: Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer (clinicaltrials.gov) - Dec 13, 2018
P1/2, N=54, Recruiting, Sponsor: M.D. Anderson Cancer Center
- | Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
New P2 trial, Metastases: COMBI-R2: Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma (clinicaltrials.gov) - Nov 27, 2018
P2, N=63, Recruiting, Sponsor: Universitair Ziekenhuis Brussel
- | hydroxychloroquine / Generic mfg.
Phase classification, Surgery, Metastases: Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery (clinicaltrials.gov) - Sep 24, 2018
P1, N=20, Completed, Sponsor: Rutgers, The State University of New Jersey
Not yet recruiting --> Recruiting Phase classification: P=N/A --> P1
- | Avastin (bevacizumab) / Roche
Trial completion, Enrollment change, Combination therapy: FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer (clinicaltrials.gov) - Aug 22, 2018
P1/2, N=50, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Phase classification: P=N/A --> P1 Active, not recruiting --> Completed | N=35 --> 50
- | hydroxychloroquine / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed, Enrollment change, Combination therapy: A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer (clinicaltrials.gov) - Aug 22, 2018
P1/2, N=119, Active, not recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Active, not recruiting --> Completed | N=35 --> 50 Recruiting --> Active, not recruiting | N=40 --> 119
- | Zolinza (vorinostat) / Merck (MSD)
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Hydroxychloroquine + Vorinostat in Advanced Solid Tumors (clinicaltrials.gov) - Aug 14, 2018
P1, N=72, Active, not recruiting, Sponsor: Sukeshi Patel
Recruiting --> Active, not recruiting | N=40 --> 119 Recruiting --> Active, not recruiting | N=48 --> 72 | Trial completion date: Sep 2018 --> Sep 2020 | Trial primary completion date: Jul 2018 --> Jul 2019
- | hydroxychloroquine / Generic mfg., docetaxel / Generic mfg., gemcitabine / Generic mfg.
New P1/2 trial, Combination therapy: Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov) - Jul 26, 2018
P1/2, N=31, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center